Clinical Trials
Enrolling Trials
71-80 of 92
for
"cancer"
Optimal Perioperative Therapy for Incidental Gallbladder
Cancer (OPT-IN): A Randomized Phase II/III Trial
Husak, Michael
Stomach, Intestine, Gut - Bile Duct, Gall Bladder
Adult
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.
Wilson, Anna E
(715) 858-6860
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
EA3161, A Phase II/III Randomized Study of Maintenance
Nivolumab Versus Observation in Patients With Locally
Advanced, Intermediate Risk HPV Positive OPCA
Lee, David
Head/Neck
Adult
This phase II/III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether chemotherapy and radiation therapy followed by maintenance nivolumab therapy works better than chemotherapy and radiation therapy alone in treating patients with HPV positive oropharyngeal cancer.
Kidwell, Anna
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
A022104-The Janus Rectal Cancer Trial: A Randomized
Phase II Trial Testing The Efficacy of Triplet Versus Doublet
Chemotherapy to Achieve Clinical Complete Response in
Patients With Locally Advanced Rectal Cancer
Edmund, Joseph
Stomach, Intestine, Gut - Rectum
Adult
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX (leucovorin, fluorouracil, oxaliplatin, and irinotecan ), and CAPOX (capecitabin and oxaliplatin) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. FOLFOX or CAPOX are used after chemoradiation as usual treatment for rectal cancer. Giving FOLFIRINOX after chemoradiation may increase the response rate and lead to higher rates of clinical complete response (with a chance of avoiding surgery) compared to FOLFOX or CAPOX after chemoradiation in patients with locally advanced rectal cancer.
Rowland, Alicia
Rozumialski, Christina
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
A Phase III Trial of Perioperative Versus Adjuvant
Chemotherapy for Resectable Pancreatic Cancer
Fagbemi, Seth O
Stomach, Intestine, Gut - Pancreas
Adult
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Rowland, Alicia
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI 54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
The CompassHER2 Trials (Comprehensive Use of
Pathologic Response Assessment to Optimize Therapy in
HER2-Positive Breast Cancer) CompassHER2 Residual
Disease (RD), a Double-Blinded, Phase III Randomized
Trial of T-DM1 Compared With T-DM1 and Tucatinib
Husak, Michael
Breast - Breast
Adult
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
Randomized Phase III Study of Combination Osimertinib
(AZD9291) and Bevacizumab Versus Osimertinib
(AZD9291) Alone as First-Line Treatment for Patients With
Metastatic EGFR-Mutant Non-Small Cell Lung Cancer
(NSCLC)
Abdelhadi, Kareem H
Lung - Lung
Adult
This phase III trial compares the effect of bevacizumab and AZD9291 (osimertinib) combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI 54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
APOLLO: A Randomized Phase II Double-Blind Study of
Olaparib Versus Placebo Following Adjuvant
Chemotherapy in Patients With Resected Pancreatic
Cancer and a Pathogenic BRCA1, BRCA2 or PALB2
Mutation
Abdelhadi, Kareem H
Rare Tumors - Pancreas
Adult
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Wilson, Anna E
(715) 858-6860
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
Phase III Study of Local or Systemic Therapy
INtensification DIrected by PET in Prostate CAncer
Patients with Post-ProstaTEctomy Biochemical Recurrence
(INDICATE)
Yeboah, Isaac
Bladder, Prostate, Kidney - Prostate
Adult
This phase III trial compares the addition of apalutamide, with or without targeted radiation therapy, to standard of care treatment versus standard of care treatment alone in patients with prostate cancer biochemical recurrence (a rise in the blood level of prostate-specific antigen [PSA] after treatment with surgery or radiation). Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT), may help doctors look for cancer that has spread to the pelvis. Androgens can cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET/CT results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Kidwell, Anna
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
S1608, Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Edmund, Joseph
Lymph Gland - Non-Hodgkin's
Other Blood Cancers - Non-Hodgkin's
Adult
This randomized phase II trial studies how well obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.
Wilson, Anna E
(715) 858-6860
Wilson, Anna E
(715) 858-6860
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI 54701
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
NRG-GU008, Randomized Phase III Trial Incorporating
Abiraterone Acetate with Prednisone and Apalutamide and
Advanced Imaging Into Salvage Treatment for Patients with
Node-Positive Prostate Cancer After Radical Prostatectomy
Fagbemi, Seth O
Bladder, Prostate, Kidney - Prostate
Adult
This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or slow the growth of prostate cancer cell growth by blocking the androgens. Abiraterone acetate blocks some of the enzymes needed for androgen production and may cause the death of prostate cancer cells that need androgens to grow. Prednisone may help abiraterone acetate work better by making tumor cells more sensitive to the drug. Adding apalutamide and abiraterone acetate with prednisone to the usual usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading or extend time without disease spreading compared to the usual approach.
Revels, Cheryl M
(715) 389-4177
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI 54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476